PTC Therapeutics (PTCT) Stock Price
PTC Therapeutics Price
Revenue has compounded at 48.3% per year over the past 23 years to 1.73 B USD. PTC Therapeutics's net margin stands at 39.4%, up from -97.3% several years earlier. Analysts set a median price target of 108.00 USD, implying 70.8% above the current price. Of 21 analysts, 17 rate the stock a buy — an overall Buy consensus.
PTC Therapeutics stock price
PTC Therapeutics business model & stock analysis
Frequently asked questions about PTC Therapeutics
PTC Therapeutics Inc.'s business model revolves around researching, developing, and commercializing innovative therapies for rare genetic disorders. The company focuses on utilizing its expertise in RNA biology and small molecule pharmacology to develop treatments that address the underlying cause of diseases. PTC Therapeutics Inc. aims to increase the production of functional proteins in patients with genetic disorders by targeting RNA splicing or protein translational regulation. Through strategic partnerships, clinical trials, and regulatory approvals, PTC Therapeutics Inc. strives to bring transformative treatments to patients with limited therapeutic options, ultimately improving their quality of life.
PTC Therapeutics Inc is primarily active in the biotechnology and pharmaceutical industries.
The main competitors of PTC Therapeutics Inc in the market are companies like Sarepta Therapeutics, Vertex Pharmaceuticals, and BioMarin Pharmaceutical.
PTC Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of orally administered small molecule drugs. Founded in 1998, PTC Therapeutics initially focused on RNA biology and identified a new class of RNA-modulating small molecules. Since its inception, the company has been committed to addressing the unmet medical needs of patients with rare and genetic disorders. Today, PTC Therapeutics is a global leader in the development of treatments for rare diseases, with a portfolio that includes multiple therapies targeting various genetic mutations. Through its innovative approach, PTC Therapeutics aims to improve the lives of patients worldwide.
PTC Therapeutics Inc has achieved several significant milestones. One notable accomplishment includes the approval of their drug, Translarna™ (ataluren), by the European Medicines Agency (EMA). This groundbreaking treatment is designed to address the underlying cause of nonsense mutation Duchenne muscular dystrophy (nmDMD). Additionally, PTC Therapeutics Inc has successfully expanded its global footprint by establishing commercialization agreements for Translarna™ in various countries. These achievements highlight PTC Therapeutics Inc's commitment to advancing innovative therapies and improving the lives of patients with genetic disorders like nmDMD.
PTC Therapeutics Inc is primarily present in various countries and regions across the globe. As a pharmaceutical company, PTC Therapeutics Inc operates in multiple markets to ensure patient access to its innovative therapies. The company's presence extends to regions such as North America, including the United States and Canada, as well as Europe, with a focus on countries like Germany, France, and Italy. PTC Therapeutics Inc continues to expand its presence in other international markets, driven by its commitment to improving the lives of patients worldwide.
PTC Therapeutics Inc represents core values of innovation, dedication, and patient-centricity. With a strong corporate philosophy, the company is committed to developing transformative therapies for patients with rare diseases caused by genetic mutations. PTC Therapeutics Inc focuses on leveraging cutting-edge science and technology to develop targeted treatments, addressing unmet medical needs. By fostering collaboration and embracing a patient-first approach, PTC Therapeutics Inc strives to improve the quality of life for individuals and families affected by these rare and debilitating conditions. Through their relentless pursuit of scientific advancements, PTC Therapeutics Inc demonstrates their commitment to making a meaningful difference in the lives of patients worldwide.
Analysts currently set an average price target of 106.14 USD for the PTC Therapeutics stock (median: 108.00 USD), implying +67.9 % versus the latest price. The consensus is based on 21 analyst ratings.
21 analysts currently rate the PTC Therapeutics stock: 17 recommend buying, 3 holding and 1 selling. For 2026, analysts expect PTC Therapeutics to generate revenue of 1.26 B USD and earnings per share of 1.25 USD.
Converted at the current exchange rate, the PTC Therapeutics share trades at 56.43 EUR (63.23 USD).
The PTC Therapeutics share (PTCT) is listed on 5 stock exchanges, including: NASDAQ (PTCT), SIX (Zürich) (P91.SW), Frankfurt (BH3.F), München (BH3.MU), Düsseldorf (BH3.DU).
PTC Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of therapies for rare diseases. The company was founded in 1998 and is headquartered in South Plainfield, New Jersey, USA. PTC Therapeutics Inc offers various products and solutions to treat diseases and conditions that are often neglected due to their rarity. These products are offered in three main areas: transcriptional regulation, DNA modification, and RNA technology. The products range from drugs to diagnostic tests to medical devices. In the transcriptional regulation division, PTC Therapeutics Inc is working on the development of small molecule drugs to regulate genes associated with various genetic diseases such as Duchenne muscular dystrophy (DMD) and cystic fibrosis (CF). The most well-known product developed in this area is Translarna (Ataluren), which is approved for the treatment of Duchenne muscular dystrophy. The second area, DNA modification, focuses on developing therapies to correct targeted mutations in the genome. This includes the CRISPR/Cas9 system, which enables targeted genome editing. Along with RNA technology, which is the focus of the third area of the company, new possibilities for treating rare diseases are emerging. PTC Therapeutics Inc has already entered into various collaborations with biotech companies such as GenEdit, Censa Pharmaceuticals, and Beam Therapeutics. Another important core product of PTC Therapeutics Inc is the SMA360 diagnostic test, which aims to identify newly diagnosed infants and toddlers with spinal muscular atrophy (SMA). SMA360 is being developed in collaboration with Invitae and Biogen, and it enables fast and precise diagnosis of SMA. Due to its advanced pipeline and diversified product portfolio, PTC Therapeutics Inc has already achieved several milestones. In 2018, the company received approval for Emflaza in the US, a drug for the treatment of DMD. Further clinical trials are in the development phase. In terms of PTC Therapeutics Inc's business model, the development and commercialization of therapies for rare diseases are an important part. PTC Therapeutics Inc has a diversified product portfolio consisting of drugs, diagnostic tests, and medical devices. The company also collaborates with other companies in the biotech industry and partners with startups and universities in the research and development field. PTC Therapeutics Inc has experienced impressive growth in recent years and has the potential to develop and implement innovative therapies and solutions for rare diseases. The company has not only drawn interest in the industry but also from investors and is facing promising challenges in the future.
The expected revenue of PTC Therapeutics is 1.26 B USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of PTC Therapeutics is 100.93 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of PTC Therapeutics is currently 50.55. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the PTC Therapeutics stock.
The price-to-sales ratio (P/S) of PTC Therapeutics is currently 4.06. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the PTC Therapeutics stock.
The Eulerpool Quality Score for PTC Therapeutics is 7/10.
The ISIN of PTC Therapeutics is US69366J2006. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of PTC Therapeutics is A1W0MW. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of PTC Therapeutics is PTCT. The ticker symbol is used to trade PTC Therapeutics shares on the stock exchange.
PTC Therapeutics stock
PTC Therapeutics Peer Group
PTC Therapeutics Ticker
PTC Therapeutics FIGI
All fundamentals and in-depth analysis of PTC Therapeutics
Our stock analysis for PTC Therapeutics stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of PTC Therapeutics. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.